Harvard Bioscience Names New Chief Financial Officer

Harvard Bioscience Announces CFO Transition

Cambridge, MA - Harvard Bioscience, Inc. (Nasdaq: HBIO), a global leader in the development, manufacture, and sale of research and clinical products, today announced that Chief Financial Officer (CFO) Mark W. Blum will be stepping down from his role, effective May 15, 2023.

Blum has served as CFO since 2019 and has played a key role in the company's financial strategy and operations. During his tenure, Harvard Bioscience has made significant progress in expanding its product portfolio, improving operational efficiency, and strengthening its financial position.

The company has begun a search for a new CFO and will provide updates on the transition process in the coming weeks. In the interim, Harvard Bioscience's Chief Executive Officer, Dr. James F. Heineman, will assume the CFO responsibilities.

"We are grateful for Mark's contributions to Harvard Bioscience and appreciate his dedication to the company," said Dr. Heineman. "We are committed to ensuring a smooth transition and are confident that Mark's expertise will be invaluable as we continue to drive growth and innovation in the years to come."

Harvard Bioscience, Inc. is a global leader in the development, manufacture, and sale of research and clinical products. The company's products are used in a wide range of applications, including basic and applied research, drug discovery, and clinical trials. For more information, please visit www.harvardbioscience.com.